171 related articles for article (PubMed ID: 37130865)
1. Metabolism-based targeting of MYC via MPC-SOD2 axis-mediated oxidation promotes cellular differentiation in group 3 medulloblastoma.
Martell E; Kuzmychova H; Kaul E; Senthil H; Chowdhury SR; Morrison LC; Fresnoza A; Zagozewski J; Venugopal C; Anderson CM; Singh SK; Banerji V; Werbowetski-Ogilvie TE; Sharif T
Nat Commun; 2023 May; 14(1):2502. PubMed ID: 37130865
[TBL] [Abstract][Full Text] [Related]
2. Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137.
Wang J; Sui Y; Li Q; Zhao Y; Dong X; Yang J; Liang Z; Han Y; Tang Y; Ma J
Cell Death Dis; 2020 Dec; 11(12):1029. PubMed ID: 33268769
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma.
Venkataraman S; Alimova I; Balakrishnan I; Harris P; Birks DK; Griesinger A; Amani V; Cristiano B; Remke M; Taylor MD; Handler M; Foreman NK; Vibhakar R
Oncotarget; 2014 May; 5(9):2355-71. PubMed ID: 24796395
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma.
Vo BT; Li C; Morgan MA; Theurillat I; Finkelstein D; Wright S; Hyle J; Smith SMC; Fan Y; Wang YD; Wu G; Orr BA; Northcott PA; Shilatifard A; Sherr CJ; Roussel MF
Cell Rep; 2017 Mar; 18(12):2907-2917. PubMed ID: 28329683
[TBL] [Abstract][Full Text] [Related]
5. Dissecting super-enhancer driven transcriptional dependencies reveals novel therapeutic strategies and targets for group 3 subtype medulloblastoma.
Li M; Han Y; Wang C; Kang W; Jiang W; Zhang L; Tang Y
J Exp Clin Cancer Res; 2022 Oct; 41(1):311. PubMed ID: 36273157
[TBL] [Abstract][Full Text] [Related]
6. The Interaction of Myc with Miz1 Defines Medulloblastoma Subgroup Identity.
Vo BT; Wolf E; Kawauchi D; Gebhardt A; Rehg JE; Finkelstein D; Walz S; Murphy BL; Youn YH; Han YG; Eilers M; Roussel MF
Cancer Cell; 2016 Jan; 29(1):5-16. PubMed ID: 26766587
[TBL] [Abstract][Full Text] [Related]
7. A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma.
Chaturvedi NK; Kling MJ; Griggs CN; Kesherwani V; Shukla M; McIntyre EM; Ray S; Liu Y; McGuire TR; Sharp JG; Band H; Joshi SS; Coulter DW
Mol Cancer Ther; 2020 Jun; 19(6):1351-1362. PubMed ID: 32371591
[TBL] [Abstract][Full Text] [Related]
8. NOTCH ligands JAG1 and JAG2 as critical pro-survival factors in childhood medulloblastoma.
Fiaschetti G; Schroeder C; Castelletti D; Arcaro A; Westermann F; Baumgartner M; Shalaby T; Grotzer MA
Acta Neuropathol Commun; 2014 Apr; 2():39. PubMed ID: 24708907
[TBL] [Abstract][Full Text] [Related]
9.
Tao R; Murad N; Xu Z; Zhang P; Okonechnikov K; Kool M; Rivero-Hinojosa S; Lazarski C; Zheng P; Liu Y; Eberhart CG; Rood BR; Packer R; Pei Y
Cancer Res; 2019 Apr; 79(8):1967-1980. PubMed ID: 30862721
[TBL] [Abstract][Full Text] [Related]
10. MYC Promotes Aggressive Growth and Metastasis of a WNT-Medulloblastoma Mouse Model.
Hartley R; Phoenix TN
Dev Neurosci; 2024; 46(3):167-178. PubMed ID: 37544301
[TBL] [Abstract][Full Text] [Related]
11. Metabolic rewiring in MYC-driven medulloblastoma by BET-bromodomain inhibition.
Graziani V; Garcia AR; Alcolado LS; Le Guennec A; Henriksson MA; Conte MR
Sci Rep; 2023 Jan; 13(1):1273. PubMed ID: 36690651
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral heterogeneity of MYC drives medulloblastoma metastasis and angiogenesis.
Qin N; Paisana E; Langini M; Picard D; Malzkorn B; Custódia C; Cascão R; Meyer FD; Blümel L; Göbbels S; Taban K; Bartl J; Bechmann N; Conrad C; Gravemeyer J; Becker JC; Stefanski A; Puget S; Barata JT; Stühler K; Fischer U; Felsberg J; Ayrault O; Reifenberger G; Borkhardt A; Eisenhofer G; Faria CC; Remke M
Neuro Oncol; 2022 Sep; 24(9):1509-1523. PubMed ID: 35307743
[TBL] [Abstract][Full Text] [Related]
13. Somatic cell transfer of c-Myc and Bcl-2 induces large-cell anaplastic medulloblastomas in mice.
Jenkins NC; Rao G; Eberhart CG; Pedone CA; Dubuc AM; Fults DW
J Neurooncol; 2016 Feb; 126(3):415-24. PubMed ID: 26518543
[TBL] [Abstract][Full Text] [Related]
14. Mouse medulloblastoma driven by CRISPR activation of cellular Myc.
Vo BT; Kwon JA; Li C; Finkelstein D; Xu B; Orr BA; Sherr CJ; Roussel MF
Sci Rep; 2018 Jun; 8(1):8733. PubMed ID: 29880921
[TBL] [Abstract][Full Text] [Related]
15. Anti-proliferative activity of the quassinoid NBT-272 in childhood medulloblastoma cells.
von Bueren AO; Shalaby T; Rajtarova J; Stearns D; Eberhart CG; Helson L; Arcaro A; Grotzer MA
BMC Cancer; 2007 Jan; 7():19. PubMed ID: 17254356
[TBL] [Abstract][Full Text] [Related]
16. Patched1 deletion increases N-Myc protein stability as a mechanism of medulloblastoma initiation and progression.
Thomas WD; Chen J; Gao YR; Cheung B; Koach J; Sekyere E; Norris MD; Haber M; Ellis T; Wainwright B; Marshall GM
Oncogene; 2009 Apr; 28(13):1605-15. PubMed ID: 19234491
[TBL] [Abstract][Full Text] [Related]
17. A microRNA-1280/JAG2 network comprises a novel biological target in high-risk medulloblastoma.
Wang F; Remke M; Bhat K; Wong ET; Zhou S; Ramaswamy V; Dubuc A; Fonkem E; Salem S; Zhang H; Hsieh TC; O'Rourke ST; Wu L; Li DW; Hawkins C; Kohane IS; Wu JM; Wu M; Taylor MD; Wu E
Oncotarget; 2015 Feb; 6(5):2709-24. PubMed ID: 25576913
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.
Diaz RJ; Golbourn B; Faria C; Picard D; Shih D; Raynaud D; Leadly M; MacKenzie D; Bryant M; Bebenek M; Smith CA; Taylor MD; Huang A; Rutka JT
Oncotarget; 2015 Feb; 6(5):3359-74. PubMed ID: 25739120
[TBL] [Abstract][Full Text] [Related]
19. Bone morphogenetic protein-7 is a MYC target with prosurvival functions in childhood medulloblastoma.
Fiaschetti G; Castelletti D; Zoller S; Schramm A; Schroeder C; Nagaishi M; Stearns D; Mittelbronn M; Eggert A; Westermann F; Ohgaki H; Shalaby T; Pruschy M; Arcaro A; Grotzer MA
Oncogene; 2011 Jun; 30(25):2823-35. PubMed ID: 21317922
[TBL] [Abstract][Full Text] [Related]
20. An animal model of MYC-driven medulloblastoma.
Pei Y; Moore CE; Wang J; Tewari AK; Eroshkin A; Cho YJ; Witt H; Korshunov A; Read TA; Sun JL; Schmitt EM; Miller CR; Buckley AF; McLendon RE; Westbrook TF; Northcott PA; Taylor MD; Pfister SM; Febbo PG; Wechsler-Reya RJ
Cancer Cell; 2012 Feb; 21(2):155-67. PubMed ID: 22340590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
